<qa>  What is the duration of the treatment phase?This is a Phase 1 and open-label study. The study consists of Screening Phase less than or equal to 28 days before Day 1, Treatment Phase Day 1 up to Day 78 and Follow up Phase 10 to 14 days after last study drug intake or, if an adverse event occurs, 30 to 35 days after last study drug intake. Treatment phase will consist of three Oral Contraceptive OC cycles each cycle consists of 21 days of ethinylestradiolnorethindrone followed by 7 pill-free days. The duration of the treatment phase, including the OC-free period of Cycles I and II, will be 78 days. Blood samples will be collected for measurement of pharmacokinetic Pk parameters. Participants safety will be monitored throughout the study. 